Real-Life Evidence on Stroke Prevention in SPAF (RELIEF)
To obtain a better understanding on the comparative effectiveness of rivaroxaban and vitamin K antagonists (VKA) for stroke prevention in patients with non-valvular atrial fibrillation (SPAF) in a real-life setting
- Age ≥18 years on the day of the first prescription of the study drug (= index date) during study selection window - Diagnosis of NVAF on start date of study or anytime during 365 days before this date - Availability of follow-up at least 180 days after the date of the first prescription of study drug within selection window of study (exposure start date) - Evidence of patient activity in the database during 90 days before the date of the first prescription of target drug within selection window.
- Patients with valvular AF - Prescriptions of Oral Anticoagulants (OACs): VKA, Dabigatran, Rivaroxaban before index date - Prescription of more than one OAC on the index date or switch to another OAC during the follow-up period - Prescriptions of < 15mg rivaroxaban at index date or during the follow-up period for patients in rivaroxaban cohort
Many Locations, Germany
E-mail: [email protected]
Phone: Not Available
REal-LIfe Evidence on Stroke Prevention in patients with Atrial Fibrillation